Regeneron CSO George Yancopoulos to Deliver Keynote Address at BBI Kick-off Event

By Stella Paffenholz

BBI is excited to announce that Dr. George Yancopoulos, MD, PhD, President and Chief Scientific Officer at Regeneron, will give the keynote speech at this year’s kick-off event on September 13. Almost 30 years ago, Dr. Yancopoulos together with Dr. Len Schleifer, MD, PhD, launched Regeneron, one of the world’s most innovate biotech companies.

Dr. Yancopoulos was always fascinated and driven by science. After attending the Bronx High School of Science, he received his MD and PhD degrees from Columbia University as a graduate student of Dr. Fred Alt, PhD, a leading figure in molecular immunology. He studied the basic genetic mechanisms how immune genes are rearranged during development. Amongst many other innovative discoveries, Dr. Yancopoulos was the first researcher to introduce human immune genes into mouse cells and show that they can be successfully rearranged. These early studies laid the foundation for the development of Regeneron’s powerful technology VelocImmune®. VelocImmune mice carry a genetically humanized immune system that enables the development of fully human monoclonal antibodies. More than a dozen antibodies developed with this system have been put into the clinic to treat various diseases, including allergic asthma, arthritis, and cancer. Other innovations spearheaded by Dr. Yancopoulos include the Trap technology and VelociGene®, a rapid and high-throughput method to genetically manipulate the mouse genome, which was exploited to generate the VelocImmune mouse.

Dr. Yancopoulos has received various honors and awards. In addition to being a member of the National Academy of Sciences and the American Academy of Arts and Sciences, he was the 11th most highly cited scientist in the world during the 1990s. Moreover, he is the first R&D chief in the pharmaceutical industry to become a billionaire.

We are looking forward to host Dr. Yancopoulos at our kick-off event to learn about his career as an innovator and experiences in the biotech industry. The event marks the beginning of BBI’s 12-week seminar series. Class participants form teams and write business plans around patented technologies invented at Cornell University, Memorial Sloan Kettering Cancer Center and Rockefeller University. At the end of the series the best teams will compete for prizes in BBI’s Annual Pitch Day Competition.


To register for the kick-off event click here.

To register for the full 12 week seminar series click here.

To look for teammates click here.


With the kick-off event approaching, BBI releases the 2017 syllabus

By Stella Paffenholz

Starting with the kick-off event on September 13th, BBI offers a 12-week course for students and professionals to learn the fundamentals of the biotech industry. The syllabus for this course has just been released (see below) and lists the BBI alumni or industry experts who participants will hear lectures from and, network with,  each week. Additionally, the syllabus summarizes the due dates for the assignments that help teams to formulate their business plans and pitches. The most successful teams will then present their final pitches to a panel of industry experts at the Pitch Day Competition on December 12th.

If you are interested in attending the BBI seminar series, click here.

To register for the Fall 2017 BBI Kickoff & Networking Event, click here.

If you have already decided to join the challenge and are looking for a team, click here.

The course syllabus is provided below*. More information can also be found on the BBI website.

Schedule: Tuesdays and/or Wednesdays, 6:00-7:30 PM @ Zuckerman Auditorium (Zrc.) (417 E. 68th St.), OR Belfer Research Building (BRB) Rooms 204 or 302 (413 E. 69th St.).

2017_syllabus*Please note that this is a tentative syllabus that may change slightly


BBI information session set to discuss Fall 2017 course and Pitch Day Competition

By Justin Morse

The Bench to Bedside Initiative (BBI) will start off the 2017 academic year with an information session this July 18th in the Belfer Research Building, room 204A, at 6:30pm. Thomas Galassi, president of BBI, will discuss the upcoming BBI course due to start this fall semester followed by a Q&A for interested participants. Tom will also answer questions about this September’s BBI kickoff event, an annual BBI event where entrepreneurs, inventors, scientists and business professionals will be able to find teammates for the December 2017 Pitch Day Competition. Pizza will be served.

BBI is composed of an interdisciplinary team from Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and Rockefeller University that works to transform basic science insights within the Tri-I community into medical innovation. To that end, the BBI offers a yearly course for professionals and students alike to learn fundamentals of the biotech industry, from designing a business plan to delivering an effective business pitch at investor meetings. Over the course of 12 weeks, participants will build a business plan around patented technologies held by the Tri-I with the help of professionals within the BBI’s extensive network. The culmination of the semester-long course is the highly anticipated Pitch Day Competition, where BBI participants deliver their business pitch to a panel of leading experts from the biotech space, venture capitalists, and consultants.

Past participants of the BBI course and winners of the 2016 Pitch Day competition include OneThreeBiotech, a company that leverages techniques in artificial intelligence to guide drug discovery and design, and iDu Optics, inventors of a microscope adapter that enables users to take high quality micrographs with iPhone cameras. In addition to winning seed funding, accounting services and a combined $25,000 in legal consultation fees from Paul Hastings LLP at the 2016 Pitch Day, both OneThreeBiotech and iDu Optics have achieved accolades beyond the BBI setting. OneThreeBiotech placed best in show at the Mid Atlantic Bio Angels (MABA) 1st Pitch Life Science Event this past March. Not long after, iDu Optics took home first prize and $25,000 of seed funding from the inaugural Dean’s Entrepreneurship Lab Biomedical Business Plan Challenge, a competition sponsored by Weill Cornell Medicine in May 2017 to foster an entrepreneurial ecosystem throughout the medical campus.

Not all BBI participants are expected to turn the skills learned throughout the course into a full-fledged biotech startup. For many, the elective complements their ongoing training as clinicians or biomedical researchers. Says President Galassi, “the BBI course is a great way for students and professionals to develop an extra set of tools beyond their formal training”, continuing that “the course is a great opportunity to learn how discoveries in the lab or clinical setting can translate into innovation within the biotech space”. The ‘Bench to Bedside: Business Fundamentals for Entrepreneurial Scientists’ course begins this fall.

Past BBI Winners Inspire New Group of Inventors for the 2017 Competition

Contributed By Mariam Giorgadze and Thomas Galassi

Last year, the Bench to Bedside Initiative (BBI) hosted its first Commercializing Life Sciences Matchmaking Event. This event teamed up scientists and clinicians with business professionals and fueled the success of participating teams in BBI’s 12 week-long course and Pitch Day competition. Following the competition, BBI’s two winning teams, iDu Optics and OneThree Biotech, successfully transitioned to compete in the Weill Cornell Medicine Dean’s Entrepreneurship Lab $50K Biomedical Business Plan Challenge, the finals of which will be held on May 10th.

This year BBI hopes that its matchmaking event will lead to even more high quality teams entering the 2017 Pitch Day Competition. Kenny Nova, an Entrepreneur and Angel Investor who participated in BBI’s 2016 Pitch Day recommends the event saying:

“This is a great opportunity for intellectually intrigued individuals who want to build something from the ground and take charge. Cornell Entrepreneurship Lab provides tremendous opportunity to investigate new inventions and cutting edge technology that’s set out to effectively and efficiently solve today’s healthcare challenges. There is a huge opportunity and need to create community around the life science inventions. No one can do this alone. Inventors can’t become business experts over night and business experts can’t absorb all the knowledge and medical expertise required either. When you look at these inventions and problems there are solving, [the] immediate need is to prioritize well and help inventors focus on [the] right issues while building the commercial application. So there is a great opportunity for both parties to complement each other. Only this can ensure successful translation of inventions and applications into commercial products and ignition of new startups.”

Anybody who is interested in ensuring the successful translation of inventions should be sure to get involved with BBI and not miss this year’s Commercializing Life Sciences Matchmaking Event on May 18th. Participants will have the opportunity to meet and mingle with Tri-institutional (Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, and Rockefeller University) inventors and industry professionals to start finding teammates for the 2017 BBI course and Pitch Day Competition.